Pfizer Reports Robust Responses for 25-Valent Vaccine Candidate in Phase 2
Pfizer said its investigational 25-valent pneumococcal conjugate vaccine candidate demonstrated robust responses in a Phase 2 pediatric study.
Pfizer said its investigational 25-valent pneumococcal conjugate vaccine candidate demonstrated robust responses in a Phase 2 pediatric study.